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Human papillomavirus (HPV) 16 and 18 are found to be involved in 80% of anal cancers. Two vaccines 
against HPV infections are currently available, and vaccination policies aim to decrease mainly, 
incidence of cervical cancers. Moreover, an impact of HPV vaccination on the incidence of anal cancer 
can also be expected. Our aim was to assess the potential benefits of HPV vaccination on the 
occurrence of female anal cancer in France. We developed a dynamic model for the heterosexual 
transmission of HPV and its progression to anal cancer in women. The model was calibrated using 
French data of anal cancer incidence. Considering vaccine coverage observed at the launch of 
vaccination campaign in France, reductions of 55 and 85% in the incidence of anal cancers due to HPV 
16/18 are to be expected in French women 30 and 50 years after vaccine introduction, respectively. In 
case of a significant decrease in vaccine coverage, a dramatic reduction in the impact of HPV 
vaccination on female anal cancers would be observed. The number of anal cancer cases in French 
women is therefore expected to decrease significantly in 30 years, assuming sustained HPV vaccine 
coverage. 
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INTRODUCTION 
 
Several western countries have recently developed 
vaccination policies against human papillomavirus (HPV) 
to prevent cervical cancer in women. It is expected that 
prevention against HPV can also dramatically decrease 
the risk of other male and female anogenital cancers. 
Therefore, the impact of HPV vaccination on non-cervical 
cancers must now be assessed. Some studies have 
considered non-cervical cancers including anal cancer 
(Elbasha and Dasbach, 2010; Jit et al., 2011). While 
epidemiological data of female anogenital non-cervical 
cancers remain sparse, some papers have reported on 
anal cancer incidence and its economic burden in 
France. For instance, the economic costs of anal cancer 
are   close  to  that  of  cervical  cancer,  despite  a   lower  
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incidence (Abramowitz et al., 2010b). In 2006, 2500 
females with anal cancer were treated in French hospitals 
(Abramowitz et al., 2010b). The incidence of anal cancer 
is higher in women than in men; the French regional 
registers of cancers have published incidence rates 
varying from 0.2 to 0.7 per 100,000 in men and from 0.7 
to 1.7 per 100,000 in women (IARC, 2007). An increase 
in anal cancer incidence has been reported in the past 
decades in Denmark, Scotland and Australia (Brewster 
and Bhatti, 2006; Jin et al., 2011; Nielsen et al., 2011). As 
with cervical cancer, epidemiological studies have 
established a causal relationship between human 
papillomavirus (HPV) infections and occurrence of anal 
cancer (Castor et al., 2011). HPV 16 and/or 18 are 
related to approximately 80% of anal cancers (Franceschi 
and De Vuyst, 2009; Abramowitz et al., 2010a). 
Vaccination against HPV infections aims to decrease 
cervical cancer incidence and may reduce the occurrence 
of other cancers due to HPV infections (anogenital 
cancers  and  head  and neck cancers). Two prophylactic 
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vaccines against HPV infections are available in France 
and have been found to be highly effective in women who 
have never been infected with HPV (Paavonen et al., 
2009; Munoz et al., 2009). The quadrivalent vaccine 
protects against HPV 6/11, which are responsible for 
genital warts, and against HPV 16/18, which are 
associated with 70% of cervical cancers. The bivalent 
vaccine protects against HPV 16/18 infection. The 
efficacy of the bivalent vaccine against anal HPV 16/18 
infection has been found to be similar to vaccine efficacy 
against cervical HPV 16/18 infection in young women 
(Kreimer et al., 2011). The quadrivalent vaccine was 
found to be efficacious in prevention of anogenital lesions 
associated with HPV 16/18 in Men who have Sex with 
Men (MSM) (Giuliano et al., 2011) and in heterosexual 
men (Hillman et al., 2011). Thus a decrease in anal 
cancers due to HPV 16/18 could be expected after the 
initiation of HPV vaccination. 
In France, the permanent Vaccines Advisory 
Committees (“Comité technique des vaccinations” and 
“Conseil supérieur d’hygiène publique de France”) 
recommend vaccinating 14-year old females. Moreover, a 
catch-up program has been offered to women aged from 
15 to 23. Females eligible for the catch-up program either 
have not been sexually active yet or may report a first 
sexual relationship that occurred in the year prior to 
vaccination (Haute Autorité de Santé). 
As anal cancers usually occur several decades after 
HPV infections, in France 75% of anal cancers are 
diagnosed in individuals aged more than 65 years 
(Fédération Nationale des Centres de Lutte Contre le 
Cancer, 1992), mathematical models are useful to assess 
any expected reductions in cancer cases. In these 
models, vaccine coverage in young women is taken into 
account. 
Various dynamic models have been published to 
assess the potential impact of HPV vaccination in several 
countries focusing on cervical cancer (Dasbach et al., 
2006). A cost-effectiveness evaluation has been done in 
France using a Markov model (Bergeron et al., 2008). 
Markov model do not take into account herd immunity 
effect. Another paper assessed the impact of HPV 
vaccination on cervical cancers in French women using a 
dynamic model (Ribassin-Majed et al., 2012). To 
estimate the cost-effectiveness of vaccination policies, 
other cancers due to HPV may be considered. In the US, 
the cost-effectiveness of HPV vaccination in Men who 
have Sex with Men (MSM) has been estimated 
considering anal cancers (Kim, 2010). Elbasha et al. 
(2007, 2010) developed several dynamic models to 
assess the economic impact of quadrivalent vaccine in 
the USA including a specific model for anal cancer 
(Elbasha and Dasbach, 2010). Jit et al. (2011) compared 
the effect and cost-effectiveness of bivalent and 
quadrivalent vaccines in UK considering a model of HPV 
transmission, progression to anal cancers was taken into 
account.   To    our    knowledge,    no    dynamic    model 
 
 
 
 
assessed specifically the impact of HPV vaccination on 
anal cancers in French females. 
We estimated the potential impact of vaccination on the 
reduction of anal cancer incidence in French women. In 
this paper, we present a deterministic model for the 
heterosexual transmission of HPV and its progression to 
anal cancer in women. Several scenarios of vaccination 
were considered. Sensitivity analyses were conducted for 
all scenarios in order to assess the impact of vaccination 
considering variations in vaccine efficacy. We aimed to 
provide useful data to assess expected reductions of anal 
cancer incidence after vaccine introduction in France. 
 
 
METHODOLOGY 
 
Dynamic model structure 
 
We used Scilab-5.1.1 software (http://www.scilab.org/fr) to design a 
deterministic model for heterosexual transmission of oncogenic 
HPV types 16 and 18. HPV types 16 and 18 are included in both 
vaccines (bivalent and quadrivalent). In our modeling, they are 
modeled jointly. We developed a system of 784 ordinary differential 
equations. We set the population size in the model to 100,000 
individuals, equally divided into females and males. The 
epidemiologic model simulated heterosexual transmission of HPV-
16/18 infections in males and females, and progression to anal 
cancer for females. Modeled natural history included compartments 
of precursor lesions of anal cancer AIN I, AIN II/III (Figure 1). After 
clearance of HPV 16/18 infection, infected individuals go back to 
susceptible compartments. 
We assumed that individuals entered the sexually active 
population at 14 years old. This assumption was consistent with the 
sexual comportment of French population, 0.4% of women and 
2.4% of men have had sexual intercourse before the age of 14 
years old in 2006 (Bajos et al., 2008). Fourteen-year-old persons 
entered the model at a gender-specific and sexual activity-specific 
rate. Sexually active women could be infected with HPV 16/18 in 
the anal region if they had had sexual intercourse with men who 
were HPV infected in the anogenital region. HPV infections are 
transmitted by contact between mucosal in the anogenital region; 
we assumed that all sexual intercourse (anal or vaginal) between 
an infected man and a susceptible woman could induce HPV 
infection in female anal region. In fact, women are probably also 
infected in cervical region, potential synergy between anal and 
cervical infections have been studied (Goodman et al., 2010). 
Individuals exited the model at death (age and gender specific 
using French data) or when they reached the age of 84. The 
heterosexually mixing population was divided into 14 age groups 
([14 to 19], [20 to 24], [25 to 29], [30 to 34], [35 to 39], [40 to 44], 
[45 to 49], [50 to 54], [55 to 59], [60 to 64], [65 to 69], [70 to 74], [75 
to 79], [80 to 84]). We developed a demographic model (Hethcote, 
1997; Elbasha et al., 2007) which simulated the distribution of the 
French population. Details on the demographic model are 
described in Ribassin-Majed et al. (2012). Annual transition rates 
into age groups were defined by the demographic model.  
Each age group was divided into 4 levels of sexual behavior. The 
level of sexual activity was defined by the number of sexual 
partners in the last 12 months (0 sexual partners-including non-
sexually-active individuals-, 1 partner, between 2 and 3 partners 
and 4 partners or more in last year). Results from the French survey 
on sexual behavior were used to derive the distribution between 
groups of sexual behavior (Table A1, Appendix). Mixing between 
sexual  activity  groups  was  quantified  by  the   mixing   matrix   as  
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Figure 1. Flow diagram. Schematic representation of the dynamic model compartments corresponding to one 
age-group i (i = 1… 14) and one group of sexual activity l (i = 1… 4) in non-vaccinated population. 
 
 
 
described by Garnett and Anderson (1993), details in Appendix. 
The parameter   described the degree of mixing between sexual 
activity groups which may vary from fully assortative (   = 0, when 
individuals have sexual partners in the same sexual activity class) 
to fully random (   = 1). Mixing between sexual activity groups was 
assumed to be preferentially assortative (   = 0.4). 
 
 
Risk of infection 
 
The risk of infection by gender depends on: probabilities of 
transmission from an infected individual to a susceptible one 
( f and m ); the number of sex partners in last 12 months ( lc  = 
0, 1, 2 and 3,  4); the proportion of infected individuals in the pool 
of sexual partners according to their age-group and level of sexual 
behavior. We developed a mixing matrix kig ,,  appropriate for the 
sexually active population in France, which gives the proportion of 
individuals of gender g, in age-group i who have sexual partners in 
age-group k (Table A2, Appendix).  
 
 
Transmission model data 
 
In a fitting procedure, we derived the probabilities of HPV 16/18 
transmission per partnership (from an infected individual to a 
susceptible one) for both sexes, the clearance rate (the same in 
males and females) and age-specific progression rates to AIN1, 
AIN 2/3 and anal cancer. To assess the probabilities of HPV 
transmission and the clearance rate, our criteria of best fitting was: 
the model reproduced HPV 16/18 female and male prevalence 
within 10%. As French data for male prevalence are not available, 
we used data from USA in both sexes in order to consider 
transmission of infection between the same population (Hernandez 
et al., 2005; Nielson et al., 2009). Several sets of the 3 parameters 
(200,000), probabilities of transmission in males, females and 
clearance rate, were tested. To assess age-specific rates for 
progression of the disease, we fit the model on female age-specific 
anal cancer incidence (IARC, 2007). As HPV types 16 and 18 are 
responsible for 80% of anal cancer (Abramowitz et al., 2010a), we 
multiplied the published French incidence rate of anal cancer by 0.8 
to assess the incidence rate of anal cancer due to HPV types 16 
and 18 (in French women).  
Published data for regression rates from AIN 1 and AIN 2/3 
compartments to susceptible compartments were used (Palefsky et 
al., 1998). 
 
 
Vaccine characteristics 
 
We divided the population into vaccinated and unvaccinated 
categories. Individuals entered the model at 14 years old (being 
vaccinated or not) in susceptible compartments. Individuals in the 
youngest age groups ([14 to 19] and [20 to 24]) could be vaccinated 
after entrance into the model in accordance with the French vaccine 
program and then moved to vaccinated categories. We considered 
several vaccination scenarios. Immunity from the vaccine was 
assumed to be sustained lifelong and vaccine efficacy was 
assumed to be 90% in the base case. Thus, vaccinated individuals 
could experiment breakthrough HPV infections and may progress to 
disease (anal cancer in females). Efficacy of 90% means that 
vaccination avoids 90% of HPV infections in vaccinated individuals 
compared to non-vaccinated individuals. 
 
 
Vaccination scenarios 
 
First, we studied the vaccine coverage observed in France at the 
beginning of the vaccination campaign in 2007 to assess vaccine 
efficacy (scenario 1). Then, we assessed vaccine efficacy in 
different hypothetical situations; in scenario 2, we considered a 
lower vaccine coverage, as observed in France a few years after 
the initiation of the vaccination campaign (Fagot et al., 2011). 
Finally, in the last scenario (scenario 3), we considered a very 
pessimistic vaccine coverage. 
In the scenarios considered, vaccine coverage was assumed to 
be constant in time. We considered only individuals who received 
the 3 doses of vaccine. In the first scenario, coverage of vaccination 
(using 3 doses of vaccines) was set to that observed in France in 
2007 (Fagot et al., 2011): 30% of women aged 14 to 19 and 10% of 
women aged 20 to 24 (Table 1). Please note that these vaccine 
coverages are annual rates in the model (e.g. each year, 30% of 
women aged 14 to 19 years receive the 3 doses of vaccine), the 
corresponding   cumulative  rates  for  scenario  1  are  presented in  
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Table 1. Scenarios of vaccination considered in simulations. Vaccine coverages are annual rates.  
 
Vaccine coverage for women Scenario 1 (%) Scenario 2 (%) Scenario 3 (%) 
14-19 30* 20 5 
20-24 10 10 5 
 
*E.g.: each year, 30% of women in the age-group [14 to 19] receive the 3 doses of vaccine. 
 
 
 
 
 
 
0.8 
0.7 
0.6 
0.5 
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0.3 
0.2 
0.1 
0 
 
 
 
Figure 2. Cumulative vaccine coverages in scenario 1: 5, 10, 20, 50 and 100 years after introduction of 
vaccination assuming constant vaccine coverage. 
 
 
 
 
 
Figure 3. Anal cancer incidence in females estimated in calibration step (model without vaccination) 
(number of new cases of female anal cancer per 100,000 women). 
 
 
 
Figure 2. For instance, a few years after vaccination launch, almost 
60% of women aged 14 to 19 years could be vaccinated (3 doses), 
assuming constant vaccine coverage (Figure 2). In the second 
scenario, we considered a lower vaccine coverage in women: 20% 
of women aged 14 to 19 and 10% of women age 20 to 24 as 
observed a few years after initiation of vaccination (Fagot et al., 
2011). In the last scenario, only 5% of women aged 14 to 24 were 
completely vaccinated (with 3 doses of vaccine). 
 
 
Model validation 
 
To  validate  the  model,  we  considered  the  epidemiological  data  
before vaccination introduction and compared it with the steady-
state estimates of the deterministic model for non-vaccinated 
individuals. Probabilities of transmission of HPV 16/18 (from an 
infected individual to a susceptible one) have been estimated in our 
fitting procedure to 0.21 (female) and 0.16 (male) and the clearance 
rate has been estimated to 0.83. 
Among infected females, the rates of progression to anal cancer 
were estimated for each age-group. We compared the age-specific 
incidence of anal cancer predicted by the model with published data 
(Human Papillomavirus and Related Cancers in France; Summary 
Report, 2010; available at who.int/hpvcenter). Each age-specific 
incidence rate of anal cancer predicted by the model was similar to 
the age-specific incidence rate of anal cancer due to HPV 16/18 in 
France within a precision of 10% (Figure 3).  
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Table 2. Anal prevalence of HPV 16/18 in women in each scenario: 20, 30 and 50 years after initiation of vaccination 
(t = 0). Vaccine coverage was supposed constant in each scenario. Percentage of reduction in HPV prevalence 
compared to the case without vaccination. 
 
Anal prevalence of HPV 16/18 for women 20 years (%) 30 years (%) 50 years (%) 
Scenario 1 -58 -75 -91 
Scenario 2 -53 -70 -86 
Scenario 3 -29 -42 -58 
 
 
 
Table 3. Prevalence of HPV 16/18 in men in anogenital site in each scenario: 20, 30 and 50 years after initiation of 
vaccination (t = 0). Vaccine coverage was supposed constant in each scenario. Percentage of reduction in HPV 
prevalence compared to the case without vaccination. 
 
Prevalence of HPV 16/18 for men 20 years (%) 30 years (%) 50 years (%) 
Scenario 1 -52 -69 -87 
Scenario 2 -47 -64 -82 
Scenario 3 -24 -37 -52 
 
 
 
Sensitivity analysis 
 
Sensitivity analyses were conducted to assess the effect of 
parameter variations on model results. Although, vaccine efficacy 
was initially set to 90%, we set vaccine efficacy in sensitivity 
analyses to 60 and 40%. Thus, we studied the impact of 
vaccination on HPV prevalence and anal cancer incidence using 
low (60 and 40%) vaccine efficacies. Another sensitivity analysis 
corresponding to a variation in the sexual mixing parameter is 
described elsewhere (Ribassin-Majed et al., 2012). 
 
 
RESULTS 
 
HPV infection prevalence 
 
Both vaccination strategies considered in scenarios 1 and 
2 led to a sizeable decrease in HPV prevalence in the 
anal region among females 20, 30 and 50 years after 
vaccination introduction (Table 2). At the horizon of 20 
years after launch of vaccination, reductions in anal HPV 
prevalence (females) of 58 and 53% will be expected 
considering respectively scenario 1 and 2. Five decades 
after introduction of vaccination, anal HPV 16/18 
prevalence in females could be approximately divided by 
10 in both scenarios 1 and 2. 
The deterministic model that we developed takes into 
account the reduction of male HPV 16/18 prevalence in 
the anogenital region due to female vaccination. Table 3 
shows the expected reduction in male prevalence for 
each scenario. 
 
 
Anal cancer in females  
 
In the base-case analysis, we assumed a 90% efficacy 
for the vaccines. In scenario 1 which considers the 
vaccine  coverage  observed  in France at the initiation of 
the vaccination campaign, a 55% reduction of anal 
cancer incidence in females due to HPV 16/18 may be 
expected 30 years after the introduction of the vaccine. 
Scenario 1 predicted a 85% reduction of anal cancer 
cases due to HPV 16/18 50 years after vaccination 
launch, assuming constant vaccine coverage (Table 4 
and Figure 4).  
In scenario 2, which considers a lower vaccination 
coverage (20 and 10% respectively in women aged 14 to 
19 and 20 to 24), 50 and 80% reductions in the numbers 
of new anal cancers would be expected respectively 30 
and 50 years after vaccine introduction.  
Considering the pessimistic scenario in which 5% of 
females aged 14 to 24 years were vaccinated (scenario 
3), a 26% reduction of anal cancer incidence would be 
expected in a horizon of 30 years after initiation of 
vaccination, this reduction reached 52% in a horizon of 
50 years if vaccine coverage is constant. 
 
 
Sensitivity analyses 
 
As efficacy of vaccine was initially set to 90% in the base-
case, we considered the effect of lower vaccine efficacies 
on the incidence of anal cancer in sensitivity analyses 
(Table 4). A lower efficacy of vaccine (60%) reduced the 
impact of vaccination on anal cancer incidence. 
Considering scenario 1 with an efficacy of 60%, our 
model predicted lower reduction in anal cancer incidence 
compared to a 90% efficacy 50 years after introduction of 
the vaccine (reductions of 63 and 85%, respectively). In 
case of an efficacy of 40%, impact of vaccination would 
dramatically decrease. A 45% reduction of anal cancer 
incidence would be expected 50 years after initiation of 
vaccination whereas a 85% reduction would be reached 
with an efficacy of 90% in scenario 1 (assuming constant 
vaccine coverage). 
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Table 4. Expected reductions in incidence of anal cancer (annual number of new cases per 100,000 individuals) due to 
HPV 16/18 in French women in each scenario 20, 30 and 50 years after initiation of vaccination (t = 0) and considering 
efficacy of vaccine of 90% in base-case, 60 and 40% in sensitivity analyses.  
 
Time since introduction 
of vaccination (years) 
Vaccine efficacy (%) Scenario 1 (%) Scenario 2 (%) Scenario 3 (%) 
20 
90 -28 -24 -8 
60 -16 -13 -3 
40 -9 -7 -0 
     
30 
90 -55 -50 -26 
60 -37 -33 -16 
40 -24 -22 -10 
     
50 
90 -85 -80 -52 
60 -63 -59 -35 
40 -45 -42 -23 
 
Vaccine coverage was assumed constant in each scenario. 
 
 
 
 
 
 
 
Figure 4. Expected reductions in female anal cancer incidence (due to HPV 16/18): 20, 30 
and 50 years after launch of vaccination campaign in France (compared to anal cancer 
incidence prior to vaccination). 
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Figure 4. Expected reductions in female anal cancer incidence (due to HPV 16/18): 20, 30 and 50 years after launch 
of vaccinatio  campaign in France (compared to anal cancer incidence prior to vaccination).  
 
 
 
DISCUSSION 
 
We have developed a dynamic model to assess the 
impact of HPV vaccination on the incidence of anal 
cancer in French women using observed coverage of 
vaccination. Using deterministic modeling, we have 
estimated the potential impact of vaccination against HPV 
to prevent anal cancers. Considering the vaccine 
coverage reached at the initiation of vaccination in 
France (30% of women aged 14 to 19 years and 10% of 
women aged 20 to 24 years) are vaccinated every year, 
the incidence of anal cancer in women could be reduced 
by 55% in  the  horizon  of  30 years  and by  85%  in  the 
horizon of 50 years compared to anal cancer incidence 
prior to vaccination. We compared several scenarios of 
vaccination coverage. The first scenario corresponded to 
the vaccination coverage observed in France at the 
initiation of the vaccination campaign (Fagot et al., 2011).  
To understand the impact of vaccination, cumulative 
vaccine coverages have to be considered. In modeling, 
annual rates are used.  
The second scenario corresponded to a lower vaccine 
coverage, as described by Fagot et al. (2011) in France a 
few years after the introduction of HPV vaccines. Finally, 
in the third scenario, we considered a very low vaccine 
coverage.  In  all  scenarios, vaccine coverage in the age- 
 
 
 
 
group targeted for ongoing vaccination was assumed to 
be constant in time. In the base-case, we assumed a 
90% efficacy of vaccine, and in the sensitivity analysis we 
assessed the impact of vaccination considering lower 
efficacies of vaccine: 60 and 40%. Efficacy of HPV 
vaccination to prevent anal cancers in females decreased 
dramatically when vaccination coverage was very low. In 
addition to cervical cancer preclusion, HPV vaccination 
can also prevent anal cancer in women. Our results 
supports maintaining the vaccination coverage at a level 
no lower than that observed after vaccination 
introduction.  
Nonetheless, our findings depend on the assumptions 
made in our modeling. We considered that individuals 
entered into the sexually active population when they are 
14 years old. This assumption is consistent with the 
survey on the sexual behavior in France (Bajos et al., 
2008). Only 0.5% of the interviewed women (aged from 
18 to 69 years) declared having their first sexual 
intercourse before the age of 14 years. 
In the deterministic model that we developed, we used 
a Susceptible-Infected-Susceptible (S-I-S) structure. We 
did not assume that individuals who cleared HPV 
infection developed natural immunity against HPV. This 
approach of natural history for HPV infections has been 
used in other HPV models (Myers et al., 2000; Goldie et 
al., 2003; Kulasingam and Myers, 2003; Sanders and 
Taira, 2003; Goldie et al., 2004; Taira et al., 2004; 
Ribassin-Majed et al., 2012), whereas some other 
published models assumed natural immunity against 
HPV using Susceptible-Infected-Removed (S-I-R) 
structure (Elbasha et al., 2010). Existence and length of 
natural immunity after HPV clearance is uncertain and 
not biologically proved. The way that natural history is 
modeled has an impact on predictions (Van de Velde et 
al., 2010). Dynamic models which used SIS structure 
predict higher effectiveness of vaccine (Van de Velde et 
al., 2010). 
The model assumed constant vaccine coverage 
whereas a decrease was observed in France between 
2007 and 2009. Efficacy of vaccination was assumed to 
last lifelong. Consequently, we did not include the need 
for vaccine booster shots in our model. The protective 
effect of vaccines is known to last at least several years 
and the need for boosters is currently unknown 
(Paavonen et al., 2009; Castellsague et al., 2011).  
Using deterministic modeling, our model took into 
account the “herd immunity” effect corresponding to a 
decrease in HPV 16/18 infections and anal cancers in 
non-vaccinated subpopulations of females due to 
vaccination coverage of other individuals. 
One of the strengths of our modeling is that we 
considered the actual vaccine coverage observed in 
France. In France, vaccine coverage has been reported 
to be low and decreasing: while 33.3% of girls aged 14 in 
2007 were vaccinated with 3 doses of the vaccine, only 
23.7 and 5.4% of girls aged 14 were vaccinated, 
respectively    in   2008   and   2009   (Fagot   et   al., 2011). 
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However, cumulative rates have to be considered.  
Considering scenario 1 and assuming constant vaccine 
coverage, at the horizon of 10 years after introduction of 
vaccination, more than 60% of females aged 14 to 19 
years will have received the 3 doses of vaccine. Fifty 
years after vaccination launch, more than 70% of women 
aged 14 to 44 years will be vaccinated. In our modeling, 
vaccination rates are constant, therefore variations in 
vaccine coverage over the time could not be considered. 
The trend observed (decrease of vaccine coverage) 
could be balanced with an increase in a long term 
perspective. Controversies in HPV vaccines and others 
vaccines (e.g. Influenza H1N1 vaccine or Hepatitis B 
Vaccine) could explain the mistrust of vaccines in French 
individuals. Campaigns of information for the targeted 
population (females and their mothers) and for 
gynecologist and pediatricians may have an impact on 
the acceptance of HPV vaccination (Blödt et al., 2011; 
Hughes et al., 2011; Lutringer-Magnin et al., 2011). 
We considered 3 vaccination scenarios and confirmed 
a dramatic decrease of HPV vaccination efficacy to 
prevent anal cancer. We assumed that only individuals 
who received 3 doses of vaccine were protected against 
HPV infection. Our modeling also considered different 
values regarding the efficacy of vaccines. In the base-
case, we considered a high efficacy as observed in 
clinical trials which conducted statistical analyses in “per 
protocol” cohorts. The efficacy of vaccines in girls and 
young women who have never been infected with HPV is 
close to 100%, whereas efficacy drops significantly in 
“intention to treat” analyses (full cohort) (Rambout et al., 
2007; Paavonen et al., 2009; Munoz et al., 2010; 
Castellsague et al., 2011). We therefore considered HPV 
vaccination with different levels of efficacy in sensitivity 
analyses. In France, populations targeted by HPV 
vaccines are represented by girls aged 14 years while 
young women aged 15 to 23 years can be vaccinated in 
a catch-up program. We may assume that some of the 
targeted populations, particularly in the catch-up 
program, could have been infected with HPV prior to 
vaccination. In this case, efficacy of vaccine is expected 
to be lower than 100%. We aimed in our paper to assess 
the impact of HPV vaccination in the presence of a 
decreased vaccination efficacy due to HPV infections 
prior to vaccination. For instance, Hernandez et al. (2005) 
observed a prevalence of anal HPV infections of 12% in 
young females (age 18 to 24 years old). Some countries 
have chosen to target younger females of 9 to 12 years 
old (ECCA). 
In conclusion, to our knowledge, this analysis is the first 
to explore the potential impact of HPV vaccination on 
anal cancer incidence in France. The findings suggest 
that a 85% reduction in anal cancer incidence due to 
HPV 16/18 is expected in French women in the horizon of 
50 years assuming sustained HPV vaccine coverage 
(which corresponds to a cumulative vaccine coverage of 
60% in women aged 14 to 19 years a few years after 
vaccination launch) and full (90%) vaccine efficacy. 
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APPENDIX 
 
 
Table A1. Distribution in the model in the 4 sexual-activity groups.  
 
Group of sexual behavior 
Female  Male 
0 (%) 1 (%) 2 – 3 (%) ≥ 4 (%)  0 (%) 1 (%) 2 - 3 (%) ≥4 (%) 
Distribution 15 75* 9 1  15 75 9 1 
 
E.g. * 75% of women declared having one sexual partner in last 12 months. 
 
 
 
Table A2. Mixing matrix between age-group. Proportion of individuals who have sexual contact with partners in youngest age-
group (<), the same age-group (=) or older age group (>). e.g. *56% of women in [20 to 24] age-group have contact with men of 
the same age-group. 
 
Age group 
% Female  % Male 
< tsf ,,  > 
 < tsm ,,  > 
14 to  19 to  35 65  to  86 14 
20 to  24 5 56* 39  25 62 13 
25 to  29 7 46 47  38 46 16 
30 to  34 8 46 46  42 44 14 
35 to  39 15 41 44  45 40 15 
40 to  44 16 44 40  46 44 10 
45 to  49 16 39 45  50 35 15 
50 to  54 13 42 45  45 41 14 
55 to  59 19 42 39  46 46 8 
60 to  64 22 40 38  56 50 7 
65 to  69 17 47 36  53 39 8 
70 to  74 17 47 36  53 39 8 
75 to  79 17 47 36  53 39 8 
80 to  84 17 83   53 47 to  
 
 
 
Mixing between sexual activity groups was quantified by the mixing matrix as described by Garnett and Anderson 
(1993). The probability for someone from the sexual-behavior group l to form a partnership with someone from the 
sexual-behavior group o is defined by: 
  
lo
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CN
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
 
 
with  being the proportion of individuals in sexual-activity group o,  representing the average number of annual 
partners in group o, lo  is the Kronecker delta ( lo = 1 if l = o and lo = 0 if l o), the parameter   described the degree 
of mixing between sexual activity groups which may vary from fully assortative (  = 0, when individuals have sexual 
partners in the same sexual activity class) to fully random (  = 1). Mixing between sexual activity groups was assumed 
to be preferentially assortative (  = 0.4). 
 
 
 
